Curve Perspectives article – Rab Prinjha Rab Prinjha joined Curve Therapeutics in 2024 as Chief R&D Officer, after 25 years at GSK. In this Curve Perspectives article to mark British Science Week, Rab explains why he joined Curve, how Southampton is shaping up as a biotech hub, and the importance of collaboration in the UK […]
Curve Perspectives article – Ali Tavassoli With its powerful Microcycle platform technology, Curve Therapeutics is building a pipeline of innovative drugs with a focus on cancer, immunology and inflammation. Our Co-Founder and Chief Scientific Officer, Ali Tavassoli, explains more. Simon Kerry and I co-founded Curve in 2019 with a vision to transform the lives of […]
2024 has been a transformational year for Curve. We kicked off the year with a significant Series A financing, raising £40.5 million from a world class syndicate which includes our existing blue chip investors Advent Life Sciences and Epidarex Capital, alongside new investment from Pfizer Ventures, Columbus Venture Partners and British Patient Capital. The financing […]
Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the appointment of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer. This continues Curve’s strong momentum expanding its leadership team following the recent appointments of Andre Hoekema and Cora Griffin, joining as Chair of the Board and Head of Business Development respectively.
Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the further strengthening of its leadership team with the appointments of Andre Hoekema as Chair of the Board and Cora Griffin as Head of Business Development.
Accomplished CFO and COO with proven track record in the biotech and pharmaceutical industry Strengthens Curve’s Leadership Team following £40.5 million Series A financing Southampton, UK, 9 July 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the […]
Research led by Curve CSO Professor Ali Tavassoli’s laboratory at University of Southampton Landmark paper on dual HIF-1 and HIF-2 inhibitor that works by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β Southampton, UK, 26 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening […]
Southampton, UK, 21 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces activity at the following scientific and investor conferences during April 2024. Anglonordic Life Science Conference, London, United Kingdom 18 April 2024 Attending: Simon Kerry, Chief […]
Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the close of its successful £40.5 million Series A financing. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital.
Dr Price brings over 20 years of experience in drug discovery and development, across pharma and biotech Southampton, UK, 18 September 2023 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a game-changing, functional drug discovery platform, today announces the appointment of Dr Sally Price as its Vice President of Biology. Dr […]
